Manipal College of Pharmaceutical Sciences, MAHE, Manipal, India
Dr. Gollapalle L. Viswanatha is a distinguished pharmacologist and toxicologist with over 17 years of expertise in pharmaceutical R&D, regulatory toxicology, and preclinical research. Currently serving as a Manager at ClinChoice Pvt. Ltd., Bengaluru, he has held pivotal roles in organizations like IQVIA, The Himalaya Drug Company, and Connexios Life Sciences. A prolific academic and industry contributor, Dr. Viswanatha has authored over 100 peer-reviewed articles and delivered more than 20 expert talks in global forums. As a DABT-certified and European Registered Toxicologist (ERT), his work bridges cutting-edge science with regulatory excellence. He also serves as adjunct faculty at Manipal College of Pharmaceutical Sciences, mentoring postgraduate students and contributing to academic research. His pioneering efforts in herbal drug evaluation, regulatory documentation, and systematic reviews make him a leading voice in toxicology and pharmacology. With several novel animal models to his credit, he actively influences drug discovery and translational medicine.
Professional Profile
Educational
Dr. Viswanatha holds a PhD in Pharmaceutical Sciences (2019) from JNTU Anantapur, with a dissertation focused on indigenous medicinal plants against stroke and epilepsy. He is board-certified by the American Board of Toxicology (DABT, 2023) and recognized as a European Registered Toxicologist (ERT, 2022). He completed a PG Diploma in Statistical Quality Control and earned a Six Sigma Green Belt from the Indian Statistical Institute (ISI), Bengaluru in 2017, both with Grade ‘A’. He holds an M. Pharm in Pharmacology (2008) from RGUHS, Bengaluru, graduating with 77% and was honored as the Best Outgoing Student. Additionally, he is a GATE and GPAT qualifier. His academic foundation is marked by a multidisciplinary understanding of pharmacology, quality systems, and toxicology. Throughout his academic journey, he has demonstrated a commitment to both practical research and methodological rigor, blending statistical competence with clinical relevance in drug discovery and safety sciences.
Professional Experience
Dr. Viswanatha has a robust professional background spanning regulatory toxicology, preclinical pharmacology, and data surveillance. Currently, he leads the toxicology division at ClinChoice Pvt. Ltd. (2021–present), overseeing cosmetic ingredient safety, CTD preparation, biocompatibility risk assessments, and toxicological risk evaluations. He formerly worked at IQVIA India Pvt. Ltd. (2014–2021) as a Senior Medical Data Reviewer, specializing in clinical trial surveillance and protocol compliance for myocardial infarction studies. Prior to that, he served as a Research Associate at The Himalaya Drug Company (2010–2014), standardizing herbal drug models, and as a Scientist at Connexios Life Sciences (2008–2010), handling PK, safety pharmacology, and toxicological assessments of NCEs. His interdisciplinary approach combines GLP compliance, regulatory documentation, safety evaluations, and project leadership. With broad expertise across pharmaceuticals, nutraceuticals, and cosmetics, he has contributed to product development from discovery to regulatory submission while mentoring cross-functional teams and managing end-to-end project execution.
Awards and Honors
Dr. Viswanatha has received numerous accolades throughout his academic and professional journey. He was honored with the prestigious Joe-Mae International Young Scientist Award by the AMS Society in Hong Kong (2016) and was a nominee for the Dr. Achari Award at IPSCON 2012 for his work on a novel pharyngitis animal model. He earned the title of Best Outgoing Student during his M. Pharm (2006–2008) and successfully qualified in GATE 2007, GPAT 2010 & 2011. His innovative contributions include the development of novel animal models for non-infectious pharyngitis and hemorrhoids. He has been invited for over 10 expert talks, delivered 5 hands-on workshops, and reviewed articles for over 35 high-impact journals, reflecting his standing as a respected thought leader. These honors underscore his commitment to translational pharmacology, scientific innovation, and academic mentorship, bridging traditional medicine with modern pharmacological practices.
Research Interests
Dr. Viswanatha’s research interests span preclinical pharmacology, regulatory toxicology, herbal medicine, and evidence-based drug evaluation. His work focuses on stroke, epilepsy, neurodegeneration, nephroprotection, pharyngitis, and gastrointestinal and cardiovascular pharmacology, often using rodent models. He has a strong inclination toward toxicological risk assessment (TRA), biocompatibility studies, and regulatory documentation for pharmaceuticals and cosmetics. His current pursuits involve systematic reviews and meta-analyses on both clinical and preclinical data, particularly emphasizing GABAergic modulation, anti-inflammatory agents, and flavonoids like naringin. He also contributes to safety pharmacology and real-world evidence generation. Beyond therapeutic investigations, he’s deeply involved in OECD-compliant toxicology, SCCS cosmetic safety dossiers, and ISO 10993-based device safety evaluations. His dual strength in bench science and regulatory frameworks makes his research both impactful and implementation-ready, aligning traditional pharmacological principles with global safety standards.
Research Skills
Dr. Viswanatha possesses advanced skills in in vivo and in vitro pharmacological/toxicological experimentation, including GLP-compliant animal models using rats, mice, rabbits, and guinea pigs. He is proficient in conducting acute, repeated dose, and genotoxicity studies, and safety pharmacology evaluations per ICH guidelines. He excels in meta-analysis and systematic reviews using RevMan, RoB-2, G-Power, and Newcastle-Ottawa scales, alongside regulatory documentation (CTD modules 2.4 & 2.6, CPSR, ADE/PDE/OEL assessments). He has expertise in SCCS guidelines, QSAR & AOT software tools, and data analysis using GraphPad Prism, SPSS, and Minitab. He’s also skilled in toxicological literature mining using PubMed, ECHA, PubChem, and other databases. A Six Sigma Green Belt and SQC professional, his approach blends quality systems with analytical rigor. His research strengths lie in project management, protocol development, real-world evidence integration, and regulatory toxicology strategy, making him an asset across life sciences domains.
Conclusion
Dr. Viswanatha exemplifies a rare blend of rigorous experimental pharmacology and robust regulatory toxicology. His multidisciplinary education and certifications, from PhD to international toxicology credentials, underpin his leadership in both academic and industry domains. With a strong track record in innovative animal model development, systematic reviews, and regulatory documentation, he drives preclinical-to-clinical translation effectively. His prolific publication record, awards, and advisory roles highlight a distinguished career that continues to influence global life sciences.
-
🧠 Clinical study on cisplatin‑induced nephrotoxicity in humans – PA Arunkumar et al. (2012)
-
🌿 Ethnopharmacology of Lepidium sativum Linn: A review – D Manohar et al. (2012)
-
🍃 Antioxidant & anti-inflammatory activity of Mangifera indica leaf extracts – CG Mohan et al. (2013)
-
🍊 Naringin’s neuroprotective neurobehavioral review/meta-analysis – GL Viswanatha et al. (2017)
-
🍎 Isolation of antidiabetic principle from Punica granatum rinds – V Jain et al. (2012)
-
🌳 POG‑glucose inhibits 11β‑HSD‑1 & ameliorates diet-induced diabetes – CG Mohan et al. (2013)
-
🍋 Lemongrass oil for dexamethasone-induced hyperlipidemia – VRS Kumar et al. (2011)
-
💊 Hepatoprotective activity of Hepax polyherbal formulation – VC Devaraj et al. (2011)
-
🌿 Antioxidant & antimutagenic activities of Terminalia arjuna bark – GL Viswanatha et al. (2013)
-
🩸 Rat model of hemorrhoids: anti‑hemorrhoidal study – M Azeemuddin et al. (2014)
-
💧 LC‑MS/MS quantification of flavonoids in Moringa & Raphinus – VC Devaraj et al. (2011)
-
🧠 Animal models of chemotherapy‑induced cognitive decline – J John et al. (2021)
-
💡 Bacopa monnieri + rivastigmine memory reversal in rats – AHM Thippeswamy et al. (2016)
-
🍊 Hesperidin’s neuroprotective & mitochondrial benefits – GL Viswanatha et al. (2012)
-
⚡ Anti‑epileptic activity of Punica granatum leaf extracts – GL Viswanatha et al. (2016)
-
🌲 Anxiolytic & anticonvulsant activity of Cedrus deodara – GL Viswanatha et al. (2009)
-
🧠 POG‑glucose alleviates ischemia/reperfusion brain injury – GL Viswanatha et al. (2013)
-
🧪 Anti‑ulcer effect of Raphinus sativus leaves – VC Devaraj et al. (2011)
-
🌱 Gymnema sylvestre extract improves glucose uptake – PM Kumar et al. (2016)
-
🍇 Phytochemical standardization of Punica granatum – V Jain et al. (2011)
-
🌸 Anti‑fertility activity of Tabernaemontana divaricata flowers – MA Mukhram et al. (2012)
-
🧊 Anti‑urolithiatic effect of Cedrus deodara extract – N Krishnadas et al. (2010)
-
💩 Antidiarrheal activity of Thespesia populnea bark fractions – GL Viswanatha et al. (2011)
-
🦴 Anti‑osteoporotic effect of herbal formula NR/CAL/06 – P Srikanta et al. (2011)
-
🌿 Antidiarrheal activity of Lepidium sativum seed extract – D Manohar et al. (2011)
-
🧠 Acteoside from Colebrookea – anti‑epileptic effects – GL Viswanatha et al. (2016)
-
💊 Thienotriazines: synthesis & antihistaminic activity – GL Viswanatha et al. (2012)
-
🧠 Punica granatum extract protects against I/R brain injury – GL Viswanatha et al. (2014)
-
🌱 Colebrookea oppositifolia root for stroke – cerebroprotective effect – GL Viswanatha et al. (2019)
-
💥 Anticonvulsant activity of POG‑glucose from Mangifera indica – GL Viswanatha et al. (2018)
-
💊 Mechanisms of biochanin‑A: a pharmacological review – PV Anuranjana et al. (2010)
-
🧬 Diabetic wound healing: update – R Keni et al. (2012)
-
🛡️ Cardioprotective preclinical systematic review on naringin – GL Viswanatha et al. (2023)
-
🌿 Ethnopharmacology of Lepidium sativum Linn. review – M Divanji et al. (2022)
-
🧠 Erythrina variegata bark extract: anxiolytic & anticonvulsant – G Pitchaiah et al. (2023)